ILMN stock forecast, quote, news & analysis
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications... Show more
Illumina (ILMN) Stock Analysis: Clinical Genomics Momentum Builds
Key Takeaways
- ILMN shares have stabilized in recent weeks, reflecting resilience amid biotech volatility and anticipation for Q1 2026 earnings.
- Q4 2025 results beat expectations with EPS (earnings per share) of $1.35 versus $1.25 forecast, supporting full-year 2026 revenue guidance of $4.5B–$4.6B.
- Analysts maintain a consensus Hold rating with an average price target around $130–$134.
- Focus on clinical genomics expansion drives long-term potential, with organic growth projected at 2%–4% excluding China.
- Upcoming Q1 earnings on April 30 expected to show revenue growth of about 16% year-over-year.
- Relative Strength (RS) rating improved to 82, signaling positive momentum.
Current Market Snapshot
Illumina (ILMN) stock has demonstrated steady performance in recent trading sessions, hovering in the mid-120s range within its broader 52-week spectrum. The shares have benefited from a recovering biotech sector sentiment, underpinned by solid prior-quarter results and forward-looking guidance. With a market capitalization approaching $19.5 billion and average daily volumes in the 1.8 million share range, ILMN exhibits moderate liquidity suitable for institutional interest. Investors appear cautiously optimistic ahead of the next earnings release, balancing growth prospects in genomics against macroeconomic headwinds like interest rate dynamics and regional demand variations.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top AI trading bots curated from a library of 351 total bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots are algorithmically selected as the most suitable for prevailing market conditions, featuring diverse trading styles such as real-time Signal Agents (no minimum balance, no automated risk management), customizable Virtual Agents (with risk controls), and Brokerage Agents from live accounts. Available timeframes include ultra-short intervals like 5 minutes, 15 minutes, and 60 minutes, catering to scalping, day trading, and swing strategies amid low, medium, or high volatility. Filters allow customization by technical or fundamental analysis and subscription plans. Traders can copy these high-performing bots to potentially enhance returns—explore the Trending AI Robots page for options aligned with ILMN and broader markets.
Recent Developments Driving ILMN Price Action
In the past 30 days, Illumina (ILMN) stock has traded with relative stability, gaining modestly in recent sessions amid building anticipation for its Q1 2026 earnings report scheduled for April 30. Analysts project revenue of approximately $1.07–$1.35 billion, marking up to 16% year-over-year growth, with EPS around $1.06. This follows a strong Q4 2025 performance reported in early February, where revenue hit $1.16 billion (up 5% YoY) and EPS of $1.35 surpassed estimates by 8%, though shares dipped post-release on tempered guidance perceptions.
Several factors have shaped sentiment. The company's Relative Strength rating climbed to 82 about a month ago, indicating improving technical momentum and outperformance versus peers. Analyst updates have been supportive, with consensus price targets steady near $132–$134 from 17–23 firms, leaning Hold but with highs up to $200. Earlier lifts, such as Evercore ISI to $155 and TD Cowen adjustments, underscore confidence in clinical adoption.
Price action reflects this: shares rose 0.5% in the latest session to around $128.50, following a 2% gain prior and a 4% pullback amid profit-taking, with volumes aligning to averages. Broader industry catalysts, including oncology partnerships like Tempus AI expansion and software updates (DRAGEN v4), bolstered genomics narratives, though macroeconomic pressures and China exposure tempered gains. SEC filings included a proxy statement on April 9 and minor insider activity, with no major M&A (mergers and acquisitions) or regulatory shifts reported recently. Overall, sentiment hinges on earnings delivery against high expectations, driving contained volatility.
2026 Outlook and Key Factors to Monitor
Illumina enters 2026 with revenue guidance of $4.5–$4.6 billion, implying 2%–4% organic growth excluding China, driven by expanding clinical genomics demand. Core growth levers include pediatric initiatives, oncology sequencing adoption, and software enhancements like DRAGEN, amid a shift toward enterprise-scale deployments. Investors should track China market recovery, as normalized demand could add upside, alongside cost discipline improving margins from recent expansions.
Risks encompass regulatory hurdles in key regions, competitive pressures from sequencing rivals, and macroeconomic factors impacting biotech funding. Opportunities lie in multi-omics integration and AI-driven analysis, potentially accelerating throughput. Balanced positioning in consumables (high recurring revenue) versus instruments supports resilience, with EPS growth forecasted in the mid-single digits. Monitoring quarterly execution against guidance, partnership progress, and global reimbursement trends will be crucial for assessing sustained trajectory through the year.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Aroon Indicator for ILMN shows an upward move is likely
ILMN's Aroon Indicator triggered a bullish signal on May 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 191 similar instances where the Aroon Indicator showed a similar pattern. In of the 191 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 01, 2026. You may want to consider a long position or call options on ILMN as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ILMN just turned positive on May 04, 2026. Looking at past instances where ILMN's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
ILMN moved above its 50-day moving average on April 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ILMN crossed bullishly above the 50-day moving average on April 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
ILMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where ILMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.000) is normal, around the industry mean (12.534). P/E Ratio (25.729) is within average values for comparable stocks, (92.891). Projected Growth (PEG Ratio) (2.482) is also within normal values, averaging (2.205). ILMN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (4.985) is also within normal values, averaging (17.960).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties